Trending

anaemia

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

The EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease

X

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

https://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed

X

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

https://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/

Celgene scores FDA okay for thalassaemia drug Reblozyl

Celgene scores FDA okay for thalassaemia drug Reblozyl

The FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the

X

Celgene scores FDA okay for thalassaemia drug Reblozyl

https://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/

GSK begins phase 3 trials of kidney drug

GSK begins phase 3 trials of kidney drug

Daprodustat is potential treatment for anaemia with CKD.

X

GSK begins phase 3 trials of kidney drug

https://pharmaphorum.com/news/gsk-begins-phase-3-trials-kidney-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com